Rituximab in hematopoietic cell transplantation

Bibliography

• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-14
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-65
   PubMed Web of Science ®Google Scholar
• Johnson PW, Rohatiner AZ, Whelan JS, Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995;13:140-7
   PubMed Web of Science ®Google Scholar
• Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984;311:1471-5
   PubMed Web of Science ®Google Scholar
• Fisher RI, LeBlanc M, Press OW, New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-52
   PubMed Web of Science ®Google Scholar
• Kang TY, Rybicki LA, Bolwell BJ, Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 2007;40:973-8
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Mauch P, Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999;94:3325-33
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D, Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525-33
   PubMed Web of Science ®Google Scholar
• Gribben JG, Neuberg D, Freedman AS, Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449-57
   PubMed Web of Science ®Google Scholar
• Schouten HC, Qian W, Kvaloy S, High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003;21:3918-27
   PubMed Web of Science ®Google Scholar
• Flinn IW, O'Donnell PV, Goodrich A, Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000;6:628-32
   PubMed Web of Science ®Google Scholar
• Buckstein R, Imrie K, Spaner D, Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999;26:115-22
   PubMed Web of Science ®Google Scholar
• Hicks LK, Woods A, Buckstein R, Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant 2009;43:701-8
   PubMed Web of Science ®Google Scholar
• Brugger W, Hirsch J, Grunebach F, Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004;15:1691-8
   PubMed Web of Science ®Google Scholar
• Gianni AM, Magni M, Martelli M, Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003;102:749-55
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Carlo-Stella C, High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009;43:509-11
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-93
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad L, Rodriguez MA, High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-23
   PubMed Web of Science ®Google Scholar
• Ganti AK, Bierman PJ, Lynch JC, Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005;16:618-24
   PubMed Web of Science ®Google Scholar
• Andersen NS, Pedersen LB, Laurell A, Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27:4365-70
   PubMed Web of Science ®Google Scholar
• Lim SH, Esler WV, Periman PO, R-CHOP followed by consolidative autologous stem cell transplant and low dose rituxan maintenance therapy for advanced mantle cell lymphoma. Br J Haematol 2008;142:482-4
   PubMed Web of Science ®Google Scholar
• Mangel J, Buckstein R, Imrie K, Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002;29:56-69
   PubMed Web of Science ®Google Scholar
• Hicks L, Connors JM, Mangel J, Autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow-up of a matched pair analysis. Blood 2006;108: abstract 3051
   Web of Science ®Google Scholar
• Dreyling M, Hoster E, Hermine O, European MCL Network: an update on current first line trials. Blood 2007;110: abstract 388
   Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG, Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-83
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant 2002;29:303-12
   PubMed Web of Science ®Google Scholar
• Ladetto M, Zallio F, Vallet S, Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia 2001;15:1941-9
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study. J Clin Oncol 2009;27: abstract 8509
   Google Scholar
• Lim SH, Esler WV, Zhang Y, B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. Leuk Lymphoma 2008;49:152-3
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Pecora AL, Alter RS, Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002;99:1486-8
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, Pearce R, Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992;10:1690-5
   PubMed Web of Science ®Google Scholar
• Freytes CO, Loberiza FR, Rizzo JD, Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood 2004;104:3797-803
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Ho VT, Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008;14:418-25
   PubMed Web of Science ®Google Scholar
• Kahl C, Storer BE, Sandmaier BM, Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744-8
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P, Saliba RM, Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008;111:5530-6
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005;24:2121-43
   PubMed Web of Science ®Google Scholar
• Di Gaetano N, Xiao Y, Erba E, Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001;114:800-9
   PubMed Web of Science ®Google Scholar
• Khouri IF, Lee MS, Saliba RM, Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004;32:28-35
   PubMed Web of Science ®Google Scholar
• Schultz KR, Paquet J, Bader S, HayGlass KT. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995;16:289-95
   PubMed Web of Science ®Google Scholar
• Tam CS, Bassett R, Ledesma C, Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-52
   PubMed Web of Science ®Google Scholar
• Zhang C, Todorov I, Zhang Z, Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001
   PubMed Web of Science ®Google Scholar
• Perruche S, Kleinclauss F, Tiberghien P, Saas P. B Cell allogeneic responses after hematopoietic cell transplantation: is it time to address this issue? Transplantation 2005;79:S37-39
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, Bodkin DJ, IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74
   PubMed Web of Science ®Google Scholar
• Tobinai K, Kobayashi Y, Narabayashi M, Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Ann Oncol 1998;9:527-34
   PubMed Web of Science ®Google Scholar
• Iori AP, Torelli GF, De Propris MS, B-cell concentration in the apheretic product predicts acute graft-versus-host disease and treatment-related mortality of allogeneic peripheral blood stem cell transplantation. Transplantation 2008;85:386-90
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Logan B, Wang D, Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol 2009;145:816-24
   PubMed Web of Science ®Google Scholar
• van Dorp S, Pietersma F, Wolfl M, Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant 2009;15:671-8
   PubMed Web of Science ®Google Scholar
• Arai S, Sahaf B, Jones C, Prophylactic rituximab after reduced intensity conditioning transplantation results in low chronic GVHD. Blood 2008;112: abstract 466
   Web of Science ®Google Scholar
• Sorror ML, Storer BE, Sandmaier BM, Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 2008;26:4912-20
   PubMed Web of Science ®Google Scholar
• Maris MB, Sandmaier BM, Storer BE, Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004;104:3535-42
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Zorn E, Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004;103:353-9
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Miller KH, Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005;105:2973-8
   PubMed Web of Science ®Google Scholar
• Mariette X, Roux S, Zhang J, The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86
   PubMed Web of Science ®Google Scholar
• Matsushita T, Hasegawa M, Yanaba K, Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006;54:192-201
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 2007;13:6107-14
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009;113:3865-74
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT, Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006;108:756-62
   PubMed Web of Science ®Google Scholar
• Sahaf B, Boiko J, Chen G, Rituximab infusion two months after HCT decreases alloreactive B cell responses while recipient plasma cells persist. Blood 2008;112: abstract 2234
   Web of Science ®Google Scholar
• Ratanatharathorn V, Carson E, Reynolds C, Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275-9
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C, Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-11
   PubMed Web of Science ®Google Scholar
• Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 2004;104:2603-6
   PubMed Web of Science ®Google Scholar
• Okamoto M, Okano A, Akamatsu S, Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-3
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F, Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007;40:273-7
   PubMed Web of Science ®Google Scholar
• Mohty M, Marchetti N, El-Cheikh J, Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 2008;41:909-11
   PubMed Web of Science ®Google Scholar
• von Bonin M, Oelschlagel U, Radke J, Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab. Transplantation 2008;86:875-9
   PubMed Web of Science ®Google Scholar
• Faye A, Van Den Abeele T, Peuchmaur M, Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998;352:1285
   PubMed Web of Science ®Google Scholar
• Svoboda J, Kotloff R, Tsai DE. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl Int 2006;19:259-69
   PubMed Web of Science ®Google Scholar
• Milpied N, Vasseur B, Parquet N, Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11(Suppl 1):113-6
   PubMedGoogle Scholar
• Clave E, Agbalika F, Bajzik V, Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004;77:76-84
   PubMed Web of Science ®Google Scholar
• Weinstock DM, Ambrossi GG, Brennan C, Preemptive diagnosis and treatment of Epstein–Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006;37:539-46
   PubMed Web of Science ®Google Scholar
• Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009;11:383-92
   PubMed Web of Science ®Google Scholar
• Rovelli A, Corti P, Balduzzi A, Prophylactic use of rituximab to prevent EBV reactivation following HSCT in patients with inherited metabolic storage diseases. Bone Marrow Transplant 2004;33: abstract 753
   Web of Science ®Google Scholar
• Bacigalupo A, Dominietto A, Soracco M, Rituximab prophylaxis of EBV reactivation after alternative donor transplants following anti-thymocyte globulin-based conditioning regimens. Blood 2008;112: abstract 2232
   Web of Science ®Google Scholar
• Boiko JR, Sahaf B, Mueller AMS, IgG allotypes reveal that antimicrobial humoral immunity persists after reduced-intensity hematopoietic cell transplantation. Blood 2008;112: abstract 349
   Web of Science ®Google Scholar
• Small TN, Robinson WH, Miklos DB. B cells and transplantation: an educational resource. Biol Blood Marrow Transplant 2009;15:104-13
   PubMed Web of Science ®Google Scholar